Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma (STRO)
:STRO
Total Valuation
Sutro Biopharma has a market cap or net worth of $62.57M. The enterprise value is ―.
Market Cap$62.57M
Enterprise Value―
Share Statistics
Sutro Biopharma has 84,461,365 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,461,365
Owned by Insiders9.09%
Owned by Institutions37.64%
Financial Efficiency
Sutro Biopharma’s return on equity (ROE) is -5.10 and return on invested capital (ROIC) is -91.69%.
Return on Equity (ROE)-5.10
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-91.69%
Return on Capital Employed (ROCE)-0.93
Revenue Per Employee230.64K
Profits Per Employee-845.58K
Employee Count269
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sutro Biopharma is -0.62. Sutro Biopharma’s PEG ratio is <0.01.
PE Ratio-0.62
PS Ratio0.00
PB Ratio1.27
Price to Fair Value3.17
Price to FCF-0.32
Price to Operating Cash Flow-0.30
PEG Ratio<0.01
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 62.04M and earned -227.46M in profits. Earnings per share was -2.96.
Revenue62.04M
Gross Profit62.04M
Operating Income-238.45M
Pretax Income-225.10M
Net Income-227.46M
EBITDA-186.81M
Earnings Per Share (EPS)-2.96
Cash Flow
In the last 12 months, operating cash flow was -191.54M and capital expenditures -3.10M, giving a free cash flow of -194.64M billion.
Operating Cash Flow-191.54M
Free Cash Flow-194.64M
Free Cash Flow per Share-2.30
Dividends & Yields
Sutro Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.71
52-Week Price Change-77.98%
50-Day Moving Average0.87
200-Day Moving Average1.90
Relative Strength Index (RSI)42.59
Average Volume (3m)1.15M
Important Dates
Sutro Biopharma upcoming earnings date is Aug 7, 2025, TBA (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Sutro Biopharma as a current ratio of 2.60, with Debt / Equity ratio of 51.91%
Current Ratio2.60
Quick Ratio2.60
Debt to Market Cap0.16
Net Debt to EBITDA0.89
Interest Coverage Ratio-7.67
Taxes
In the past 12 months, Sutro Biopharma has paid 2.36M in taxes.
Income Tax2.36M
Effective Tax Rate-0.01
Enterprise Valuation
Sutro Biopharma EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.13.
EV to Sales-0.42
EV to EBITDA0.14
EV to Free Cash Flow0.13
EV to Operating Cash Flow0.13
Balance Sheet
Sutro Biopharma has $316.89M in cash and marketable securities with $23.15M in debt, giving a net cash position of -$293.74M billion.
Cash & Marketable Securities$316.89M
Total Debt$23.15M
Net Cash-$293.74M
Net Cash Per Share-$3.48
Tangible Book Value Per Share$0.58
Margins
Gross margin is -2.80%, with operating margin of -384.34%, and net profit margin of -366.62%.
Gross Margin-2.80%
Operating Margin-384.34%
Pretax Margin-362.81%
Net Profit Margin-366.62%
EBITDA Margin-301.10%
EBIT Margin-312.73%
Analyst Forecast
The average price target for Sutro Biopharma is $1.70, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.70
Price Target Upside129.73% Upside
Analyst ConsensusHold
Analyst Count5
Revenue Growth Forecast-56.88%
EPS Growth Forecast-57.57%